DDInter93 DDInter1610
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Anagrelide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is regulated by {v} (Gene) FGFR2
FGFR2 {u} (Gene) is upregulated by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Pyridostigmine
Pyridostigmine {u} (Compound) resembles {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tapentadol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
HMG20B {u} (Gene) is regulated by {v} (Gene) GDPD5
GDPD5 {u} (Gene) is upregulated by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is regulated by {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) upregulates {v} (Gene) IKBKE
IKBKE {u} (Gene) regulates {v} (Gene) FGFR2
FGFR2 {u} (Gene) is upregulated by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) upregulates {v} (Gene) IKBKE
IKBKE {u} (Gene) regulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Anagrelide {u} (Compound) upregulates {v} (Gene) RHOA
RHOA {u} (Gene) covaries with {v} (Gene) STXBP2
STXBP2 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Rivastigmine (Compound)
Anagrelide (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Rivastigmine (Compound)
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is regulated by FGFR2 (Gene) and FGFR2 (Gene) is upregulated by Rivastigmine (Compound)
Anagrelide (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Rivastigmine (Compound)
Anagrelide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tapentadol (Compound) and Tapentadol (Compound) resembles Rivastigmine (Compound)
Anagrelide (Compound) upregulates HMG20B (Gene) and HMG20B (Gene) is regulated by GDPD5 (Gene) and GDPD5 (Gene) is upregulated by Rivastigmine (Compound)
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is regulated by GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Rivastigmine (Compound)
Anagrelide (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) regulates FGFR2 (Gene) and FGFR2 (Gene) is upregulated by Rivastigmine (Compound)
Anagrelide (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) regulates GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Rivastigmine (Compound)
Anagrelide (Compound) upregulates RHOA (Gene) and RHOA (Gene) covaries with STXBP2 (Gene) and STXBP2 (Gene) is downregulated by Rivastigmine (Compound)